Evidence map›Paper›PMID 27552910›Full record

ReviewMayo Clinic proceedings2016

New Developments in Clinical Bacteriology Laboratories.

Robin Patel

Registry-linked trialOpen access · bronzeAbstract readReview
In one paragraph

Review in Mayo Clinic proceedings, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05686577 (Comment Diminuer Les hémocultures Inutiles), which is not on this map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05686577 completednot on this mapstarted 2022, after this paper: background citation

Comment Diminuer Les hémocultures Inutiles : Construction et Validation d'un Score prédictif de positivité Des hémocultures en réanimation.

TypeobservationalSponsorUniversity Hospital, ToursRan2022 to 2023Enrolled2,411ConditionsInfection, Bacterial, Infection, Fungal, BacteremiaArmsno intervention
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 50 citations in OpenAlex.

  1. DecipheringMicroorganisms · 2026
    Review
  2. Article
  3. Proteomics in the Diagnosis of Viral and Pathogenic Infections.Advances in experimental medicine and biology · 2026
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Role of Lymphangiogenesis in Cardiac Repair and Regeneration.Methodist DeBakey cardiovascular journal · 2023
    Review
  9. Article
  10. A discussion of syndromic molecular testing for clinical care.The Journal of antimicrobial chemotherapy · 2021
    Article
  11. Review
  12. Peritonitis fromClinical case reports · 2019
    Article
  13. Review
  14. Syndromic Panel-Based Testing in Clinical Microbiology.Clinical microbiology reviews · 2018
    Review
  15. Article
  16. The lung microbiome in health and disease.Clinical medicine (London, England) · 2017
    Review
  17. Carbapenem-Resistant Enterobacteriaceae.Clinics in laboratory medicine · 2017
    Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Robin PatelDivision of Clinical Microbiology, Department of Laboratory Medicine and Pathology, and Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, MN. Electronic address: patel.robin@mayo.edu.
Mayo Clinic in Arizona · US

Funding

Antibacterial Resistance Leadership Group (ARLG)UM1AI104681 · NIAID · DUKE UNIVERSITY · PI Vance G. Fowler, Henry F HENRY CHAMBERS · 2013 to 2026
$180.8M
NIAID NIH HHS UM1 AI104681
6 · The paper itself

Abstract

There are a number of changes underway in modern clinical bacteriology laboratories. Panel-based molecular diagnostics are now available for numerous applications, including, but not limited to, detection of bacteria and select antibacterial resistance markers in positive blood culture bottles, detection of acute gastroenteritis pathogens in stool, and detection of selected causes of acute meningitis and encephalitis in the cerebrospinal fluid. Today, rapid point-of-care nucleic acid amplification tests are bringing the accuracy of sophisticated molecular diagnostics closer to patients. A proteomic technology, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, is enabling rapid, accurate, and cost-effective identification of bacteria, as well as fungi, recovered in cultures. Laboratory automation, common in chemistry laboratories, is now available for clinical bacteriology laboratories. Finally, there are several technologies under development, such as rapid phenotypic antimicrobial susceptibility testing, whole-genome sequencing, and metagenomic analysis for the detection of bacteria in clinical specimens. It is helpful for clinicians to be aware of the pace of new development in their bacteriology laboratory to enable appropriate test ordering, to enable test interpretation, and to work with their laboratories and antimicrobial stewardship programs to ensure that new technology is implemented to optimally improve patient care.

Indexed as

Microbiological TechniquesMolecular Diagnostic TechniquesAutomation, LaboratoryHumansMicrobiologyNucleic Acid Amplification TechniquesPoint-of-Care SystemsProteomics

Identifiers

PMID27552910
PMCPMC5786463
OpenAlexW2510816326

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.